Drug-induced liver injury (DILI) represents a major challenge for the pharmaceutical industry and regulatory authorities, as it is a major problem in both the early and later stages of the drug development process, and the most common cause of post-marketing warnings and withdrawals. Its strategic location and outstanding role in the metabolism of xenobiotics renders the liver particularly susceptible to potential toxic effects of a drug and/or its metabolites. 	zebrafish hepatoxicity assay services	https://zebrafish.creative-biogene.com/zebrafish-hepatoxicity-assay.html